| Carleen M Poellinger, CNM | |
|
1836 South Ave, La Crosse, WI 54601-5429 | |
| (608) 782-7300 | |
| Not Available |
| Full Name | Carleen M Poellinger |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 25 Years |
| Location | 1836 South Ave, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780688143 | NPI | - | NPPES |
| 39908200 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 129428 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gundersen Lutheran Medical Center Inc | 2163331414 | 800 |
| Gundersen Lutheran Medical Center Inc | 2163331414 | 800 |
News Archive
Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.
BioNeutral Group, Inc. has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company's strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
Children with a particular variation in the CYT19 gene metabolize arsenic differently than adults with the same genetic variant, according to a new research report. The findings have important implications for the safety of drinking water worldwide and the use of arsenic as a cancer drug.
Correctly diagnosing Alzheimer's disease remains a challenge for medical professionals. Now, a new study published in the current issue of the Journal of Alzheimer's Disease reveals a new clue to possible misdiagnosis.
› Verified 9 days ago
| Entity Name | Gundersen Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.
BioNeutral Group, Inc. has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company's strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
Children with a particular variation in the CYT19 gene metabolize arsenic differently than adults with the same genetic variant, according to a new research report. The findings have important implications for the safety of drinking water worldwide and the use of arsenic as a cancer drug.
Correctly diagnosing Alzheimer's disease remains a challenge for medical professionals. Now, a new study published in the current issue of the Journal of Alzheimer's Disease reveals a new clue to possible misdiagnosis.
› Verified 9 days ago
| Entity Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.
BioNeutral Group, Inc. has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company's strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
Children with a particular variation in the CYT19 gene metabolize arsenic differently than adults with the same genetic variant, according to a new research report. The findings have important implications for the safety of drinking water worldwide and the use of arsenic as a cancer drug.
Correctly diagnosing Alzheimer's disease remains a challenge for medical professionals. Now, a new study published in the current issue of the Journal of Alzheimer's Disease reveals a new clue to possible misdiagnosis.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carleen M Poellinger, CNM 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Carleen M Poellinger, CNM 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.
BioNeutral Group, Inc. has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company's strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
Children with a particular variation in the CYT19 gene metabolize arsenic differently than adults with the same genetic variant, according to a new research report. The findings have important implications for the safety of drinking water worldwide and the use of arsenic as a cancer drug.
Correctly diagnosing Alzheimer's disease remains a challenge for medical professionals. Now, a new study published in the current issue of the Journal of Alzheimer's Disease reveals a new clue to possible misdiagnosis.
› Verified 9 days ago
Pamela L Tennant, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Agnes E Hoeger, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Meggan Lynn Scanlan, MSN, APRN, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1900 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Rebecca K Kearns, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Joyce E Belgum, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kathy L. Errthum, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-782-9760 | |
Amy Belling-dunn, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |